Lack of ROS1 gene rearrangement in glioblastoma multiforme

Sun Min Lim, Junjeong Choi, Jong Hee Chang, Jinyoung Sohn, Kristine Jacobson, Frank Policht, John Schulz, Byoung Chul Cho, Se Hoon Kim

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor, and the prognosis remains poor. Rearrangement of ROS1 gene, which was shown to have an oncogenic potential, was previously discovered in GBM cell lines. In this pilot study, we aimed to identify the incidence of ROS1 rearrangement in GBM patient tissues to explore novel biomarkers for therapeutic strategy. Formalin-fixed and paraffin-embedded (FFPE) tissue sections from 109 patients with GBM were screened for ROS1 rearrangement by anti-ROS immunohistochemistry (IHC) and ROS1 break-apart fluorescent in situ hybridization (FISH) assays. O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation and Isocitrate dehydrogenase 1 (IDH1) mutation status were also assessed. All samples were interpreted by two experienced pathologists who were blinded to the clinical data. A total of 109 samples were collected and all samples were examined for ROS1 rearrangement by IHC and FISH assays, and none was found to harbor ROS1 rearrangement. MGMT gene methylation was found in 42 (39.2%) cases, and IDH1 mutation was found in 6 (5.5%) cases. In this study, ROS1 rearrangement was not identified in GBM patients, and thus it is difficult to classify ROS1 rearrangement as a novel molecular subset in GBM patients for now.

Original languageEnglish
Article numbere0137678
JournalPloS one
Volume10
Issue number9
DOIs
Publication statusPublished - 2015 Sep 14

Bibliographical note

Funding Information:
This study was funded in part by Novartis Pharmaceuticals. Jinyoung Sohn is employed by JEUK Co., Ltd. John Schulz is employed by Abbott Molecular Diagnostics. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Publisher Copyright:
© 2015 Lim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

All Science Journal Classification (ASJC) codes

  • General

Fingerprint

Dive into the research topics of 'Lack of ROS1 gene rearrangement in glioblastoma multiforme'. Together they form a unique fingerprint.

Cite this